Helsinn has provided new positive data presented at the ECCO-ESMO joint European oncology conference in Berlin, for palonosetron. Palonosetron, a second generation 5-HT3 receptor antagonist, which improves emesis
Boehringer Ingelheim with its US animal health business Boehringer Ingelheim Vetmedica, has entered into an agreement with Pfizer to acquire certain assets of Wyeth Pharmaceutical’s Fort Dodge Animal
Ion Beam Applications SA (IBA) and Aposense has entered into an collaboration agreement for commercialising Aposense [18F]–ML-10, Aposense’s novel agent for molecular imaging of apoptosis. The agreement includes
Sanofi Pasteur, the vaccines division of the sanofi-aventis Group, has received an additional order from the US Department of health and human services (HHS) to produce vaccine to
Genomic Health has declared results from the first study to compare the distribution of Oncotype DX Recurrence Score results between European, Middle Eastern and the US patient populations.
ACTEGA Rhenania has developed a novel series of solvent-free polyurethane adhesives for laminates to be used in packaging. Compared to classical solvent-borne polyurethane adhesives there is no need
Amgen has revealed detailed results from the phase 3 181 trial evaluating Vectibix in combination with Folfiri, as a second-line treatment for metastatic colorectal cancer. In this trial,
BioMarin Pharmaceutical has initiated treatment in the phase 2 clinical study of PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase) for the treatment of phenylketonuria (PKU). The initial top-line results
Roche has revealed an analysis of its phase II BRAIN study of Avastin (bevacizumab) alone or in combination with irinotecan chemotherapy for the treatment of relapsed or progressive
Nektar Therapeutics presented positive data on lead oncology program, NKTR-102, demonstrating encouraging phase 1 and preclinical anti-tumor activity of the investigational compound in ovarian cancer. These data were
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.